IN the 12 years since the last review of herpes simplex virus (HSV) infections in these pages,
1 there have been substantial advances in our knowledge of the clinical manifestations, …

Background The safety and efficacy of the AZD1222 (ChAdOx1 nCoV-19) vaccine in a large,
diverse population at increased risk for severe acute respiratory syndrome coronavirus 2 (…

Background Nucleoside analogues against herpes simplex virus (HSV) have been shown
to suppress shedding of HSV type 2 (HSV-2) on genital mucosal surfaces and may prevent …

Background Vaccines are needed to prevent coronavirus disease 2019 (Covid-19) and to
protect persons who are at high risk for complications. The mRNA-1273 vaccine is a lipid …

Reports have focused on the emergence of moulds as pathogens in recipients of hematopoietic
stem cell transplants. To review the incidence of and risks for mould infections, we …

In the coronavirus efficacy (COVE) phase 3 clinical trial, vaccine recipients were assessed
for neutralizing and binding antibodies as correlates of risk for COVID-19 disease and as …

Background The Ad26.COV2.S vaccine is a recombinant, replication-incompetent human
adenovirus type 26 vector encoding full-length severe acute respiratory syndrome coronavirus …

Background At interim analysis in a phase 3, observer-blinded, placebo-controlled clinical
trial, the mRNA-1273 vaccine showed 94.1% efficacy in preventing coronavirus disease 2019 …

Background Observational data and non-human primate challenge studies suggest that cell-mediated
immune responses might provide control of HIV replication. The Step Study …

Zidovudine (AZT) is a potent inhibitor of the replication of the human immunodeficiency virus
(HIV), and it has been shown to improve survival in advanced HIV disease. We conducted a …